trial

Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia

NCTId NCT00793780
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 24 (actual)
Sponsored by Yale University
Primary completion 2010-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
24 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-12
Primary completion
2010-11
Eligibility
FEMALE · 18 Years · 70 Years

Interventions & indications

Drugs
Naltrexone 25mg

Sponsors

Yale UniversityLead Sponsor
Ethel F. Donaghue Women's Health Investigator Program at YaleCollaborator

Investigators

1
Cenk Tek, M.D.Principal Investigator

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
24
Phase
NA
Primary Completion Date
2010-11
Status
COMPLETED
relationships
The graph out of here
drug
Naltrexone 25mg
drug
lead_sponsor
Yale University
company
collaborator
Ethel F. Donaghue Women's Health Investigator Program at Yale
company
indication
Obesity
indication
Schizoaffective Disorder
indication
Weight Loss
indication
investigator
Cenk Tek, M.D.
person